Participants

Digit span forward scores

Verbal fluency scores


 
Baseline Mean (SD)

12 months Mean (SD)

Supplemented vs. placebo Mean diff. (95% CI)

Baseline Mean (SD)

12 months Mean (SD)

Supplemented vs. placebo Mean diff. (95% CI)


All participants

Supplemented

11.0 (2.2) (n 455)

11.5 (2.3) (n 398)

0.1 (0.3, 0.2)

32.1 (12.0) (n 454)

33.8 (12.8) (n 397)

0.8 (0.3, 2.0)


Placebo

11.2 (2.2) (n 450)

11.7 (2.1) (n 374)
 
31.7 (12.8) (n 450)

33.0 (13.3) (n 372)
 
Participants aged 75 years or over

Supplemented

10.8 (2.2) (n 144)

11.1 (2.3) (n 123)

0.1 (0.8, 0.6)^{1}

30.0 (12.7) (n 143)

32.4 (13.0) (n 123)

2.8 (0.6, 6.2)^{1}


Placebo

11.0 (2.1) (n 146)

11.3 (2.2) (n 105)
 
29.6 (12.5) (n 146)

30.0 (13.4) (n 103)
 
Participants at increased risk of deficiency

Supplemented

10.8 (2.1) (n 144)

11.2 (2.4) (n 113)

0.4 (0.3, 1.1)^{1}

29.2 (12.0) (n 144)

31.3 (13.1) (n 113)

2.5 (1.0, 6.1)^{1}


Placebo

10.8 (2.2) (n 116)

10.9 (2.0) (n 91)
 
30.6 (13.9) (n 116)

29.2 (13.2) (n 91)
 

^{1} Reflecting the fact that the analysis was carried out on a subgroup, a 99% confidence interval was used to give the correct width for the 95% confidence interval.